JON D. BLACHLEY, M.D.; JULIAN B. HILL, M.D.
Cisplatin is a coordinate metal complex with significant antineoplastic activity and various adverse effects, including acute and chronic renal insufficiency and renal magnesium wasting. Nephrotoxicity may occur in as many as 50% to 75% of patients receiving the drug, and is apparently due to renal tubular injury. Although controlled, prospective clinical trials are lacking, the available data indicate that the frequency and severity of cisplatin nephrotoxicity may be reduced by slow infusion rates; hydration before, during, and immediately after administration of cisplatin; and concomitant administration of mannitol. Preliminary animal studies indicate that chloride-containing vehicles such as 0.9% sodium chloride may prevent the aquation or hydroxylation of cisplatin and reduce its toxicity. No information is available on the prevention of cisplatin associated renal magnesium wasting. However, frequent measurement of serum cations and appropriate replacement are recommended.
BLACHLEY JD, HILL JB. Renal and Electrolyte Disturbances Associated with Cisplatin. Ann Intern Med. 1981;95:628–632. doi: 10.7326/0003-4819-95-5-628
Download citation file:
Published: Ann Intern Med. 1981;95(5):628-632.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use